You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
百奧泰(688177.SH):注射用BAT2022獲批臨牀試驗
格隆匯 06-10 17:05

格隆匯6月10日丨百奧泰(688177.SH)公佈,公司於近日收到國家藥品監督管理局核准簽發的關於公司在研藥品注射用BAT2022的《臨牀試驗批准通知書》。

注射用BAT2022是由百奧泰自主研發的雙特異性中和抗體,擬用於治療由於新冠病毒及其突變株感染引起的新冠肺炎。BAT2022可特異性結合病毒刺突蛋白上的兩個不同表位,從而有效地阻斷病毒侵染宿主細胞,直接阻斷病毒與宿主細胞受體血管緊張素轉化酶2(ACE2,Angiotensin Converting Enzyme2)的結合,從而阻斷病毒侵染細胞。BAT2022雙特異中和抗體具有廣譜性及高效性,在體外真病毒細胞感染實驗中對多種突變株(包括alpha,beta,gamma,delta,omicron)均有高效中和能力。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account